

---

## Contents

---

<b>Preface</b> . . . . .	ix
<b>Chapter 1. Medicines and Drugs</b> . . . . .	1
1.1. Definition of a drug. . . . .	1
1.2. A few important dates in the history of drugs . . . . .	2
1.3. Different types of drugs . . . . .	3
1.4. Classification of drugs . . . . .	7
1.4.1. ATC classification . . . . .	7
1.4.2. BCB classification (Base Claude Bernard) . . . . .	8
1.4.3. Thesorimed® . . . . .	8
1.4.4. Theriaque . . . . .	9
1.5. A few facts about the pharmaceutical industry. . . . .	9
1.6. Life cycle of a drug. . . . .	11
1.6.1. Molecular modeling . . . . .	11
1.6.2. Chemical studies, synthesis and the first “pharmacological filters” . . . . .	12
1.6.3. Clinical trials . . . . .	13
1.6.4. Engineering studies . . . . .	13
1.6.5. Regulatory studies . . . . .	13
1.7. Marketing authorization application . . . . .	15
1.8. Chemistry, R&D and drug design . . . . .	16
<b>Chapter 2. Importance and Evaluation of the pKa</b> . . . . .	21
2.1. Definition of the pKa and its implications . . . . .	21
2.2. Examples. . . . .	26

---

2.3. Case of zwitterions . . . . .	27
2.4. Influence of structure . . . . .	28
2.4.1. Structural factors which alter the pKa . . . . .	28
2.4.2. Consequences of electronic effects. . . . .	32
2.5. Evaluating the pKa . . . . .	33
2.5.1. Physico-chemical methods . . . . .	33
2.5.2. Method by fast increments . . . . .	34
2.5.3. Hansch's method . . . . .	40
2.6. What is the relevance of the pKa for absorption when a drug is administered orally? . . . . .	49
<b>Chapter 3. Importance and Evaluation of Lipophilicity . . . . .</b>	<b>53</b>
3.1. Passing through a membrane. . . . .	53
3.1.1. Fluid membrane. . . . .	53
3.1.2. Passive diffusion of amines . . . . .	55
3.2. Evaluating lipophilicity. . . . .	57
3.2.1. Flash-shaking method . . . . .	58
3.2.2. Chromatography method . . . . .	58
3.2.3. Incremental method. . . . .	59
3.3. Use of software. . . . .	66
3.4. General points: logD . . . . .	68
3.4.1. Definitions . . . . .	68
3.4.2. Variation of logD as a function of the pH. . . . .	71
3.4.3. Lipophilic efficiency . . . . .	71
3.5. Hydrophilic–Lipophilic Balance (HLB): a galenic problem . . . . .	73
3.5.1. Definition. . . . .	73
3.5.2. Calculating the HLB . . . . .	73
<b>Chapter 4. Importance and Evaluation of Solubility . . . . .</b>	<b>79</b>
4.1. Definitions . . . . .	79
4.2. Evaluating solubility on the basis of lipophilicity . . . . .	80
4.2.1. Method using the logP . . . . .	81
4.2.2. Comparison of the different calculation methods . . . . .	82
4.3. Methods by contribution of groups or fragmentation . . . . .	83
4.4. Case of ionizable substrates . . . . .	85
4.5. Solubility and “druggability” . . . . .	86
4.6. How to modify solubility . . . . .	87

---

<b>Chapter 5. Importance and Evaluation of the Polar Surface Area (PSA and TPSA)</b> . . . . .	89
5.1. Definitions . . . . .	89
5.2. Evaluating the polar surface area. . . . .	90
5.2.1. Evaluation of the TPSA by summation. . . . .	90
5.2.2. Case of heterocycles. . . . .	93
5.3. Influences of PSA and TPSA on different physico-chemical properties . . . . .	94
5.3.1. TPSA and drug design . . . . .	94
5.3.2. Passage through the BBB and the gastro-intestinal tract . . . . .	94
5.4. Use of software . . . . .	95
<b>Chapter 6. Lipinski's Rule of Five</b> . . . . .	97
6.1. What does Lipinski's rule say? . . . . .	98
6.2. Veber's rule . . . . .	98
<b>Chapter 7. Principle of a Prodrug</b> . . . . .	101
7.1. Introduction . . . . .	101
7.2. Bioprecursor. . . . .	102
7.3. Vector prodrug . . . . .	104
7.3.1. Definition . . . . .	104
7.3.2. First objective: rendering the drug hydrosoluble. . . . .	106
7.3.3. Second objective: rendering the drug more lipophilic . . . . .	109
7.3.4. Slow release of the drug by cascade hydrolysis. . . . .	110
7.3.5. Planned release of the drug by hydrolysis by anchimeric assistance . . . . .	112
7.3.6. Modern use of the prodrug principle: ADEPT . . . . .	113
<b>Chapter 8. Pharmacophore</b> . . . . .	119
8.1. Definition . . . . .	119
8.2. 3D pharmacophore . . . . .	121
8.3. Metabophore and toxicophore . . . . .	123
8.4. Modification of the structure . . . . .	125
8.4.1. The concept of bioisosteres. . . . .	125
8.4.2. Homologation . . . . .	130
8.4.3. Functional group inversion. . . . .	130

<b>Chapter 9. The European Pharmacopoeia</b> . . . . .	135
9.1. Introduction . . . . .	135
9.2. Description of a monograph . . . . .	136
9.2.1. Identification reaction . . . . .	136
9.2.2. Groups of reactions included under the title “tests” . . . . .	139
9.2.3. Dosage reactions . . . . .	141
9.2.4. Control of impurities . . . . .	141
<b>Glossary</b> . . . . .	145
<b>Bibliography</b> . . . . .	151
<b>Index</b> . . . . .	159